Currently Viewing:
American Society of Clinical Oncology (ASCO) 2017
Dr Barbara McAneny on How the COME HOME Model Helps Cut Hospitalization Rates
June 14, 2017
Real-World Treatment Patterns Highlight Need for Clinical Education on PD-L1 Testing in NSCLC
June 13, 2017
Can the 4 Ps Devise Interventions to Reduce the Financial Toxicity of Cancer?
June 06, 2017
Dr Barbara McAneny Outlines Collaboration With ASCO on COME HOME Model
June 05, 2017
Daratumumab With Standard Regimen Improves PFS in Multiple Myeloma, Independent of Cytogenetic Risk
June 05, 2017
MACRA 2.0 and Beyond: Preparing Your Practice to Meet the Quality and Reporting Challenges
June 05, 2017
Dr Craig Portell Highlights New and Exciting Treatments for Non-Hodgkin's Lymphoma
June 05, 2017
Dr Edward Li Discusses the Benefit Biosimilars Can Have in Oncology
June 04, 2017
Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer
June 04, 2017
Do We Have Adequate Surveillance in Cancer Survivor Care?
June 04, 2017
Dr Basit Chaudhry on Experiences in the Oncology Care Model and Early Indications of Success
June 04, 2017
Currently Reading
Dr Scott Ramsey: Value Frameworks Are Moving Toward Harmonization
June 03, 2017
Patient Selection Vital in Ensuring Improved Response to PD-1, PD-L1 Inhibitors in NSCLC
June 03, 2017
Dr Daniel George Highlights Successes of Checkpoint Inhibitors in Prostate, Bladder Cancers
June 03, 2017
ASCO Study Finds Shift in Diagnosis Stage for Several Cancers Following ACA Implementation
June 01, 2017
HPV Vaccination May Lower Prevalence of Oropharyngeal Cancers in Young Adults
May 31, 2017

Dr Scott Ramsey: Value Frameworks Are Moving Toward Harmonization

Value frameworks aren't at an ideal point in their development, yet, but it is important to keep in mind that different frameworks represent different perspectives, said Scott Ramsey, MD, PhD, of Fred Hutchinson Cancer Research Center.


Value frameworks aren't at an ideal point in their development, yet, but it is important to keep in mind that different frameworks represent different perspectives, said Scott Ramsey, MD, PhD, of Fred Hutchinson Cancer Research Center.

Transcript

Finding common ground among stakeholders when using value frameworks has been difficult. Do you think we're any closer to an ideal or well-balanced value framework?

I think we are closer, we aren’t at an ideal, but the important thing that’s happened with value frameworks is that the organizations that are involved in providing care and financing care have been more explicit about their preferences. So the value frameworks that you see from organizations like ASCO {American Society of Clinical Oncology] and NCCN [National Comprehensive Cancer Network] represent the perspectives of those organizations. And just clarifying that is an important step towards finding harmonization.

What changes would you like to see within the existing frameworks in oncology, such as NCCN, Institute for Clinical and Econommic Review, and ASCO?

The initial thing I would like to see them do is be more transparent about what they’re accounting for in terms of costs and outcomes and also to understand the perspective that they’re taking when they make judgments about those particular aspects of the value frameworks. Those of us in cost-effectiveness generally favor the quality-adjusted life-year [QALY] and a more complete accounting of costs than most of the existing value frameworks that aren’t based on cost per QALY, and I think we need more explicit understanding of where those frameworks are coming from before we can move forward.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!